Compare CET & ARDX Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
| Metric | CET | ARDX |
|---|---|---|
| Founded | 1929 | 2007 |
| Country | United States | United States |
| Employees | N/A | N/A |
| Industry | Finance/Investors Services | Biotechnology: Pharmaceutical Preparations |
| Sector | Finance | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 1.5B | 1.6B |
| IPO Year | N/A | 2014 |
| Metric | CET | ARDX |
|---|---|---|
| Price | $50.40 | $5.70 |
| Analyst Decision | | Strong Buy |
| Analyst Count | 0 | 7 |
| Target Price | N/A | ★ $15.14 |
| AVG Volume (30 Days) | 36.2K | ★ 3.5M |
| Earning Date | 01-01-0001 | 05-12-2026 |
| Dividend Yield | ★ 5.34% | N/A |
| EPS Growth | ★ N/A | N/A |
| EPS | ★ N/A | N/A |
| Revenue | N/A | ★ $2,607,000.00 |
| Revenue This Year | N/A | $38.22 |
| Revenue Next Year | N/A | $33.85 |
| P/E Ratio | $6.93 | ★ N/A |
| Revenue Growth | ★ N/A | N/A |
| 52 Week Low | $40.24 | $3.50 |
| 52 Week High | $52.95 | $8.40 |
| Indicator | CET | ARDX |
|---|---|---|
| Relative Strength Index (RSI) | 37.29 | 36.62 |
| Support Level | $49.88 | $5.49 |
| Resistance Level | $51.02 | $6.23 |
| Average True Range (ATR) | 0.88 | 0.26 |
| MACD | -0.16 | -0.04 |
| Stochastic Oscillator | 11.85 | 9.41 |
Central Securities Corp is a non-diversified closed-end management investment company. Its investment objective is long-term growth of capital. The company invests in common stocks, bonds, convertible bonds, preferred stocks, convertible preferred stocks, warrants, options real estate, or short-term obligations of governments, banks, and corporations.
Ardelyx Inc is a biopharmaceutical company developing and commercialize, first-in-class medicines that meet unmet medical needs. It has developed a platform that enabled the discovery of new biological mechanisms and pathways to develop potent and efficacious therapies that minimize the side effects and drug-drug interactions frequently encountered with traditional, systemically absorbed medicines. It product Tenapanor, branded as IBSRELA, is used for the treatment of adults with IBS-C. Tenapanor, branded as XPHOZAH, is used to reduce serum phosphorus in adults with CKD on dialysis as add-on therapy in patients who have an inadequate response to phosphate binders or who are intolerant of any dose of phosphate binder therapy.